Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Guanabenz in pediatric vanishing white matter disease
NL-OMON60546Phase 2Completed
- Sponsor
- Amsterdam University Medical Center
- Start
- May 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of guanabenz in leukoencephalopathy with vanishing white matter (VWM), sponsored by Amsterdam University Medical Center. Primary endpoint: Safety and tolerability. Started May 2021; status: completed.
02
Drugs
guanabenz
03
Conditions
leukoencephalopathy with vanishing white matter (VWM)
Beyond the preview
Go deeper on NL-OMON60546.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60546.